Indian drug manufacturing companies need to make continuous efforts to maintain quality:Dr Vadlamudi

The Indian drug manufacturing companies need to take more efforts to continue to maintain the quality compliance once they reached a quality level as per the regulatory norms. It is difficult to permanently adhere to the compliance norms, either big player or micro unit, unless consistent attempt is made for it, said Dr. VSV Vadlamudi, president of the Indian Pharmaceutical Association (IPA).
 
In an interview with Pharmabiz in Indore, he said IPA is now dedicated to sensitise the industry more than ever for maintaining quality compliance. He said those manufacturers who want to stick to quality norms in their continuous drug productions need to have three qualities such as, proper mindset for quality maintenance, investment capacity and skilled human resources. Unless these three, no company could be able to maintain its quality for long.
 
Earlier, while sharing the dais at the inaugural ceremony of the IPA-MP Conclave and Pharma Tech Expo 2015, he said unlike other countries, India produces two kinds of pharmacists, pharmacists for practice of pharmacy profession and pharmacists as pharmaceutical scientists for manufacturing industry, clinical trials and research organisations.
 
He said India has a unique position in the production and marketing of drugs among other countries. But, the country needs to create quality medicines, for which government should formulate new packages or plans for the industry to sustain. Similarly, best pharmaceutical care should be provided to all kinds of patients and the pharmacists should have significant role in the healthcare management of the country.
 
According to him, the WHO guidelines are interpreted differently by the manufacturers and the regulators. It has to be made transparent. The manufacturers should follow the norms of regulations. If they want to export their products, they have to follow the requirements of the regulatory bodies of other countries also. He said India is exporting drugs to regulated markets, semi-regulated markets and to the rest of the world.
 
Dr. Subhash C Mandal, chairman of the regulatory affairs division of the IPA, said the regulatory affairs of India need to be updated as there are so many confusions among the manufacturers and regulators.

Source: Pharmabiz